April 13, 2021

iCE Neurosystems Raises $2.95 Million in New Seed Round

Deep Tech Startup to Accelerate Hospital Adoption and Analyze Data  

iCE Neurosystems, a neurotechnology startup that has created a revolutionary platform to diagnose and prevent brain injury in critically-ill patients, recently announced the acquisition of $2.95 million from private investors.

With two FDA-cleared platform components, a growing patent portfolio and total fundraising approaching $4.5 million to date, iCE Neurosystems is on the cusp of transforming brain health for every American.

“iCE Neurosystems is dedicated to building the world’s largest integrated brain and body dataset for critically-ill patients, and investors are taking note,” said Dr. Allen Waziri, neurological surgeon and CEO/Co-Founder. “While we are working through the final stages of the contracting process with several major hospitals, this new funding will take our efforts to the next level, helping us further accelerate hospital adoption and scale our data analysis program.”  

The physician-founders of iCE Neurosystems have leveraged decades of combined clinical and research experience to develop the iCEWav Neuromonitoring Platform. Requiring no specialized training and designed for use at the bedside or in tele-ICU settings, iCEWav combines proprietary minimally invasive devices, first-in-class data integration and custom cloud software to drive AI-based clinical decision support.

While trauma is often assumed to be the primary source of brain injury, over 90% of severe brain injuries occur in non-trauma conditions such as stroke, brain hemorrhage, cardiac arrest, heart failure or sepsis. 

Many of these brain injuries – and the billions of dollars of associated costs to hospitals and society – could be avoided with iCEWav by providing doctors relevant data in real-time to initiate targeted clinical intervention. iCE Neurosystems estimates that up to 2.5 million people per year in the U.S. could benefit from iCEWav’s brain monitoring technology. 

This oversubscribed funding round will be used for accelerating clinical adoption, scaling commercialization, expanding big data capabilities and other early growth deliverables that will support acquisition of Series A funds within the next 12-24 months.